# Prevention of preterm birth in twin pregnancies - "Randomised trial of progesterone versus placebo"

Submission date 11/10/2015	Recruitment status  No longer recruiting	[X] Prospectively registered			
		<pre>Protocol</pre>			
Registration date 19/11/2015	Overall study status Completed	Statistical analysis plan			
		[X] Results			
Last Edited	Condition category	Individual participant data			
26/01/2021	Pregnancy and Childbirth				

### Plain English summary of protocol

Background and study aims

It has been found that the more babies a pregnant mother is carrying, the more likely she is to give-birth early (preterm). Complications for the baby are usually very small, as most preterm births take place after 32 weeks. If the babies are born earlier than this, it can lead to heart, breathing or brain problems. Progesterone is a hormone which is naturally produced in a woman's body. It plays an important part during pregnancy by helping to nurture the foetus and maintain the womb (uterus) through pregnancy. Studies have shown that progesterone can help to protect against preterm births in women carrying one baby (singleton pregnancy). So far this does not appear to be the case when a woman is carrying twins, however this may be because it is given too late during pregnancy at too low a dose. There are many types of progesterone available, and so the type used may also have an impact on its effectiveness at preventing preterm births. The aim of this study is to find out whether the progesterone containing product Utrogestan can help to prevent preterm births in women carrying twins.

### Who can participate?

Women over 18 years of age who are pregnant with twins.

### What does the study involve?

Participants are randomly allocated to one of two groups. The first group are asked to insert suppositories (a capsule which is placed in the vagina) containing 300mg progesterone twice a day until 34 weeks gestation (pregnancy) or earlier if the baby is born prematurely. The first group are asked to insert suppositories containing a placebo (dummy) twice a day until 34 weeks gestation (pregnancy) or earlier if the baby is born prematurely. At the end of the study, the amount of babies that are born prematurely are recorded, as well as any complications, such as low birth weight, need for special care or stillbirth.

### What are the possible benefits and risks of participating?

Participants may benefit from the potential effect of progesterone in preventing preterm delivery. Not all participants will gain benefit because half of them will receive a placebo drug. Irrespective of which treatment group participants are assigned to, they will benefit from the

close monitoring that they will receive. Participants will not be denied anything they would usually receive as part of routine care by being part of this study. Risks of participating are small, however some patients may experience some mild vaginal discharge or irritation. Previous studies involving progesterone in pregnancy have not reported any side effects. Progesterone is safe for pregnant women and their fetuses throughout pregnancy and is not associated with birth defects.

Where is the study run from? Hospital Universitario "Virgen de la Arrixaca" (Spain) and six hospitals in the UK

When is the study starting and how long is it expected to run for? March 2015 to March 2018

Who is funding the study? Fetal Medicine Foundation (UK)

Who is the main contact?

- 1. Dr Catalina De Paco (Scientific)
- 2. Professor Kypros Nicolaides (Scientific)
- 3. Miss Liona Poon (Scientific)

# Contact information

### Type(s)

Scientific

### Contact name

Dr Catalina De Paco

### Contact details

Fetal Medicine Unit Hospital Universitario "Virgen de la Arrixaca" Murcia Spain 30120

### Type(s)

Scientific

### Contact name

**Prof Kypros Nicolaides** 

### Contact details

Harris Birthright Research Centre for Fetal Medicine King's College Hospital London United Kingdom SE5 9RS

## Type(s)

Scientific

### Contact name

Miss Liona Poon

### **ORCID ID**

https://orcid.org/0000-0002-3944-4130

### Contact details

Harris Birthright Research Centre for Fetal Medicine King's College Hospital London United Kingdom SE5 9RS

### Type(s)

Scientific

### Contact name

Mr Anoop Rehal

### Contact details

Fetal Medicine Research Institute King's College Hospital 16-20 Windsor Walk London United Kingdom SE5 8BB

# Additional identifiers

Clinical Trials Information System (CTIS)

2015-005180-16

Protocol serial number

N/A

# Study information

### Scientific Title

Early vaginal progesterone for the preVention of spontaneous prEterm birth iN TwinS: A randomised, placebo controlled, double-blinded trial- EVENTS

### Acronym

**EVENTS** 

### **Study objectives**

In twin pregnancies, the use of a vaginal progesterone (urtogestan) started in the first trimester will reduce the chances of having a preterm birth before 34 weeks gestation.

### Ethics approval required

### Old ethics approval format

### Ethics approval(s)

London Bridge REC, 22/02/2016, ref: 16/LO/0066

### Study design

Multi-centre double-blind placebo-controlled randomised trial

### Primary study design

Interventional

### Study type(s)

Prevention

### Health condition(s) or problem(s) studied

Preterm birth

### **Interventions**

All women with a twin pregnancy attending for their routine first trimester scan will be invited to participate in this randomised controlled trial of progesterone versus placebo. Informed and written consent will be sought from those agreeing to participate in the study. Participants are then randomly allocated to the treatment group or the placebo group.

Treatment group: Participants are required to insert a 300mg progesterone suppository twice daily until 34 weeks' gestation or earlier in the event of preterm delivery.

Control Group: Participants are required to insert a 300mg placebo suppository twice daily until 34 weeks' gestation or earlier in the event of preterm delivery.

Follow--up clinical visits for all participants will be carried out at every 2-4 weeks. They will also be followed up by a further telephone interview 30 days after the last dose of medication.

### Intervention Type

Drug

### Phase

Phase III

## Drug/device/biological/vaccine name(s)

Utrogestan

### Primary outcome(s)

Incidence of spontaneous delivery before 34 weeks (238 days) of gestation.

### Key secondary outcome(s))

- 1. The incidence of spontaneous preterm birth <37 weeks (259 days) of gestation
- 2. Birth weight below the 3rd, 5th and 10th centile
- 3. Rate of stillbirth or neonatal death due to any cause
- 4. Major adverse outcomes before discharge from the hospital (intraventricular haemorrhage,

respiratory distress syndrome, retinopathy of prematurity, or necrotising entercolitis)
5. Need for neonatal special care (admission to a neonatal intensive care unit, ventilation, phototherapy, treatment for proven or suspected sepsis, or blood transfusion)

### Completion date

01/12/2019

# **Eligibility**

### Key inclusion criteria

- 1. Aged 18 years or over
- 2. Dichorionic diamniotic (DCDA) or monochorionic diamniotic (MCDA) twin pregnancies;
- 3. Live fetuses at 11-13 weeks of gestation;
- 4. English or Spanish speaking (otherwise interpreters will be used)

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Adult

### Lower age limit

18 years

### Sex

Female

### Total final enrolment

1194

### Key exclusion criteria

- 1. Pregnancies complicated by major fetal abnormality identified at the 11-13 weeks assessment, including nuchal translucency thickness >3.5 mm
- 2. In MCDA twin pregnancies there are early signs of twin-to-twin transfusion syndrome (TTTS) (20% discordance in crown-rump length [CRL] and/or nuchal translucency [NT])
- 3. Women who are unconscious or severely ill, those with learning difficulties, or serious mental illness
- 4. Hypersensitivity to progesterone
- 5. Concurrent participation in another drug trial or at any time within the previous 28 days
- 6. Any other reason the clinical investigators think will prevent the potential participant from complying with the trial protocol

### Date of first enrolment

02/05/2017

### Date of final enrolment

18/04/2019

# Locations

### Countries of recruitment

United Kingdom

England

Spain

Study participating centre Hospital Universitario "Virgen de la Arrixaca" Murcia Spain 30120

Study participating centre King's College Hospital London Denmark Hill London United Kingdom SE5 9RS

Study participating centre Medway Maritime Hospital Windmill Road Gillingham United Kingdom ME7 5NY

Study participating centre Southend University Hospital

Prittlewell Chase Westcliff-on-Sea United Kingdom SSO ORY

Study participating centre Homerton University Hospital Homerton Row London United Kingdom E9 6SR

Study participating centre
University Hospital Lewisham
High Street
London
United Kingdom
SE13 6LH

Study participating centre North Middlesex Hospital Sterling Way London United Kingdom N18 1QX

# Sponsor information

### Organisation

Foundation for Health Education & Research (Fundación para la Formación e Investigación Sanitaria)

### **ROR**

https://ror.org/05m5has32

# Funder(s)

### Funder type

Charity

### **Funder Name**

Fetal Medicine Foundation

# **Results and Publications**

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Data sharing statement to be made available at a later date

# Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2021	26/01/2021	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes